Table II.
Atopic dermatitis treatment characteristics at enrollment in the CorEvitas Atopic Dermatitis Registry
| Characteristics | Total |
|---|---|
| N = 2603 | |
| Current systemic treatment at enrollment,∗n (%) | N = 2603 |
| Dupilumab | 1914 (73.5%) |
| Upadacitinib | 218 (8.4%) |
| Tralokinumab-ldrm | 147 (5.6%) |
| Methotrexate | 101 (3.9%) |
| Cyclosporine | 21 (0.8%) |
| Apremilast | 16 (0.6%) |
| Abrocitinib | 13 (0.5%) |
| Mycophenolate mofetil/mycophenolic acid | 8 (0.3%) |
| Omalizumab | 5 (0.2%) |
| Tofacitinib | 2 (0.1%) |
| Tacrolimus | 1 (0.0%) |
| Other treatment at enrollment,†n (%) | N = 2603 |
| Corticosteroids | 83 (3.2%) |
| Phototherapy | 62 (2.4%) |
| Topical therapy | 1875 (72.0%) |
| History of treatment at enrollment,‡n (%) | N = 2603 |
| Systemic therapy§ | 1229 (47.2%) |
| Corticosteroids | 498 (19.1%) |
| Phototherapy | 326 (12.5%) |
| Superpotent topical steroids, topical calcineurin inhibitors, or crisaborole | 2257 (86.7%) |
| Number of systemic therapies§ before enrollment (excluding current therapy), n (%) | N = 2603 |
| 0 | 2356 (90.5%) |
| 1 | 199 (7.6%) |
| 2+ | 48 (1.8%) |
Frequencies may not sum to total as patients may be treated with multiple systemic therapies concomitantly.
Not mutually exclusive. Includes both treatment in use and treatment newly started/prescribed at enrollment.
Not mutually exclusive. Includes treatment started any time before enrollment, regardless of whether treatment is in use at enrollment.
Systemic therapy includes registry eligible biologics (tralokinumab-ldrm, dupilumab, secukinumab, ustekinumab, risankizumab-rzaa, ixekizumab, and omalizumab), eligible small molecules (abrocitinib, upadacitnib, baricitinib, apremilast, and tofacitinib), and eligible nonbiologic systemics (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, mycophenolic acid, and tacrolimus).